Benitec Biopharma BNTC 深 滬
等待開盤 09-23 09:30:00 美东时间
10.95
+0.070
+0.64%
華盛通- 最 高11.365
- 今 開10.97
- 成交量 8.89万股
- 最 低 10.61
- 昨 收 10.88
- 總市值 3.82亿
- 52周最高 16.76
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 9.85
- 委 比 34.43%
- 總股本 3488.27万
- 歷史最高 5609.5744
- 量 比 0.43
- 振 幅 6.94%
- 歷史最低 2.227
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
09-15 21:38
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
09-15 04:09
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma announced financial results for FY 2026 and provided updates on BB-301 clinical development. Cohort 1 (low dose) completed 12-month follow-up, and Cohort 2 (high dose) was fully enrolled with safe treatments. A Type C FDA meeting discussed pivotal study design, with minutes expected in October. Interim results from the Phase 1b/2a trial will be presented at the ESGCT Congress in October. The company has $180 million in cash. BB-...
09-14 20:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.
07-28 20:49
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from
05-14 20:41
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25
Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.
05-12 23:24
